Abstract: An in situ cell bioreactor and delivery system is provided. The system is composed of toroidal-spiral particles, which encapsulate cells therein and can further provide one or more active agents. Methods for using the system in cell-based therapies are also provided.

Abstract: A filter assembly for separating microcarriers from a fluid medium includes a collapsible container bounding a sterile compartment adapted to hold a fluid. An inlet port is attached to the container through which fluid flows into the compartment. An outlet port is attached to the container through which fluid flows out of the compartment. A filter is disposed within the compartment, the filter dividing the compartment into an inlet chamber that is fluidly coupled with the inlet port and an outlet chamber that is fluidly coupled with the outlet port, the filter allowing a medium to pass therethrough but preventing microcarriers disposed in the medium from passing therethrough.

Abstract: A cell culturing system configured to move a liquid sample from a cell culturing device to a sampling channel via a sample introduction channel. The sampling device includes a sampling channel having a main-mechanism-side pump disposed between a cleaning solution storage unit and the sample introduction channel and is configured to allow a cleaning solution to flow to a detection unit. The sample introduction channel includes an introduction-mechanism-side pump that is configured to allow the sample to flow from the sample introduction channel to the detection unit.

Abstract: A method for washing particles includes obtaining an array plate that includes an array of hydrophilic areas surrounded by one or more hydrophobic areas. A respective solution containing a sample is located on a respective hydrophilic area of the array of hydrophilic areas. The respective hydrophilic area includes one or more indentations from a respective surrounding hydrophobic area of the one or more hydrophobic areas. The respective hydrophilic area includes a first indented surface that is offset from a reference surface defined by the respective surrounding hydrophobic area. The method also includes placing an aspirator nozzle above the respective hydrophilic area at a predefined distance from the first indented surface, and aspirating the solution with the aspirator nozzle while the aspirator nozzle is located at the predefined distance from the first indented surface.

Abstract: A sterile foam breaking system, (14, 42, 52) includes a foam collector (20) having an opening (26), configured to be disposed in a source (12) which generates foam. The sterile foam breaking system (14, 42, 52) further includes a non-coated type suction unit (23) coupled to the foam collector (20). The non-contact type suction unit (23) is configured to transfer the foam via the opening (26) of the foam collector (20) and break a portion of the foam to generate a first quantity of liquid droplets. The sterile foam breaking system (14, 42, 52) additionally includes a foam breaking unit (28, 44, 54) coupled to the non-contact type suction unit (23). The foam breaking unit (28, 44, 54) is configured to receive remaining portion of the foam and the first quantity of liquid droplets and break the remaining portion of the foam to generate a second quantity of liquid droplets.

Abstract: A device for providing a sterile environment for the incubation of cell cultures is proposed, comprising a warming chamber with heating elements, sensors for temperature, humidity and CO2, and a gas supply providing a gas connection in the interior. The device also has a cultivation tank located in the warming chamber. This has a sealable passage for each sensor, and also a sealable gas inlet and outlet that couples to the gas connection inside the warming chamber. The sensors of the warming chamber are arranged to fit into respective passages of the cultivation vessel. The device also has a water reservoir arranged in the cultivation tank. The three elements of the warming chamber, the cultivation container and the water reservoir can be sterilized separately using the optimal method for each. Since the sensors are not part of the cultivation container, the latter can also be decontaminated by high temperatures.

Abstract: The present disclosure belongs to the technical field of temperature detection devices for microfluidic chips, specifically relates to a temperature detection device and method in loop mediated isothermal amplification (LAMP). The temperature detection device in the LAMP includes a temperature measurement mechanism, a heat conduction pad, a heating layer, and a thermal insulation layer which are disposed in sequence from top to bottom; the temperature measurement mechanism enters a corresponding temperature measurement chamber to collect corresponding working chamber temperature data, that is, the heating layer adjusts, according to the corresponding working chamber temperature data, heat generated by a corresponding heating source; the thermal insulation layer prevents the heating layer from downwards transmitting the heat such that the heats generated by the heating sources in the heating layer are all transmitted to corresponding heating regions through the heat conduction pad.

Abstract: A multiport device for connecting a loop, preferably a tangential flow filtration loop or a sensor loop, to one port of a bioreactor, preferably a single-use bioreactor, is configured to be fixed to the port of the bioreactor. The multiport device includes a first flow path configured for withdrawing fluid from the bioreactor, and a second flow path configured for supplying fluid to the bioreactor. The first flow path has a first end adapted to be in fluid connection with the bioreactor, and a second end adapted to be connected to an inlet of the loop. The second flow path has an outer end adapted to be connected to an outlet of the loop, and a mouth adapted to be in fluid connection with the bioreactor. The mouth of the second flow path is distanced from the first end of the first flow path by at least 5 mm, preferably 10 mm.

Abstract: A computer implemented method for monitoring a bioprocess comprising a cell culture in a bioreactor is provided. The method including the steps of: obtaining measurements of the amount of biomass and the amount of one or more metabolites in the bioreactor as a function of bioprocess maturity, using the measurements to determining one or more metabolic condition variables; using a pre-trained multivariate model to determine the value of one or more latent variables as a function of bioprocess maturity, wherein the multivariate model is a linear model that uses process variables including the metabolic condition variables as predictor variables and maturity as a response variable; comparing the value(s) of the one or more latent variables to one or more predetermined values as a function of maturity; and determining on the basis of the comparison whether the bioprocess is operating normally.

Abstract: The invention provides a process for producing a fermentable gas stream from a gas source that contains one or more constituent which may be harmful to the fermentation process. To produce the fermentable gas stream, the gas stream is passed through a specifically ordered series of removal modules. The removal modules remove and/or convert various constituents found in the gas stream which may have harmful effects on downstream removal modules and/or inhibitory effects on downstream gas fermenting microorganisms. At least a portion of the fermentable gas stream is preferably capable of being passed to a bioreactor, which contains gas fermenting microorganisms, without inhibiting the fermentation process.

Abstract: A portable and mobile bioprocessing system and method for protein manufacturing that is compact, integrated and suited for on-demand production of any type of proteins and for delivery of the produced proteins to patients or for assay purposes. The portable system and method can also be used for efficient on-demand production of any type of protein with point-of-care delivery.

Abstract: The present invention relates to the direct use by addition of drilling gravels residue from the oil exploration and production activities in the formulation of culture medium of unicellular organisms, increasing its growth rates, intensifying the CO2 biofixation, and generating value to this residue from of productivity gains expected by autotroph and mixotroph organisms (cyanobacteria, microalgae and macroalgae), as well as the production of bioproducts that can be generated through the concept currently described in the literature as biorefining. Algae are cultured using drilling gravel suspended in the culture medium together with the ability to grow by absorbing CO2.

Abstract: The present disclosure relates to mutant algae resistant to salicylanilide based drug. The mutant algae has improved productivity and improved photosynthetic efficiency as compared to wild type of the algae in presence of the salicylanilide based drug. The present disclosure further relates to a method of preparing said mutant algae.

Abstract: Provided for are methods of producing triacylglycerol-accumulated microalgae, methods for making bioplastics from triacylglycerol-accumulated microalgae, methods for making alga-mixed plastics, and products including these bioplastics. Methods of triacylglycerol accumulation using centrifugation are also provided. Products such as plastic beads and other consumer products can be made from the bioplastics described herein.

Abstract: The present invention relates to yeast strains of the species Saccharomyces pastorianus with the useful characteristic of producing low levels of diacetyl during fermentation. Also provided are methods of producing a malt and/or cereal based beverage with these strains, as well as beverages produced by this method.

Abstract: The present invention features general-purpose microbiological growth media capable of supporting growth of microorganisms on membranes. The media contain casein digest, soybean digest, animal tissue digest, yeast extract, dextrose, a phosphate buffer, hemin, and L-cystine. The invention features an all-purpose microbiological growth media that can support the growth of anaerobes, molds, injured spores, and general aerobic bacteria to a greater extent than other media.

Abstract: The invention provides a microbial production cell for synthesis of a product, further comprising a burden-addiction genetic circuit whose expression confers a selective growth and/or survival advantage on those cells that synthesize the product; while limiting proliferation of low- or non-productive escaper cells.

Abstract: The present disclosure provides agricultural compositions and methods of using these compositions to increase plant growth, pathogen resistance and drought tolerance. The agricultural compositions disclosed herein comprise mixtures of mutualistic beneficial fungi such as Laccaria bicolor and Piriformispora indica, and bacterial strains of Pseudomonas.

Abstract: Disclosures herein are directed to chemically defined animal-derived component free supplements designed for individual cell types that supports the ex vivo growth of cells as well or better than serum, in chemically defined conditions.

Abstract: Methods of mammalian cell culture for expressing a recombinant protein of interest are provided. In various embodiments the methods relate to the mammalian cells expressing an IGF1R mutant that is constitutively active.

Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

Abstract: The present invention provides a composition for pluripotent cell undifferentiated state maintenance culture and a culture method using the same, which are capable of improving the growth rate of pluripotent cells or reducing the frequency of cellular death of pluripotent cell in the pluripotent cell maintenance culture in an undifferentiated state. A composition for pluripotent cell undifferentiated state maintenance culture includes microbubbles.

Abstract: The present specification discloses clonal cell lines susceptible to BoNT/A intoxication, methods of producing such clonal cell lines, and methods of detecting Botulinum toxin serotype A activity using such clonal cell lines.

Abstract: The present invention relates to a mini-brain structure and a construction method therefor and, more specifically, to a mini-brain and a construction method therefor, wherein induced pluripotent stem cells can be used to prepare brain organoids for different brain regions accounting for the cerebrum, the mesencephalon, the cerebellum, the thalamus, and the like and the organoids are combined into single structures, thereby making it possible to further effectively implement actual brain functions and wherein brain organoids for different brain regions can be selectively combined into single structures according to purposes, thereby achieving the aim of using brain organoids and enhancing convenience and economical benefit.

Abstract: The method relates to an in vitro method of producing a (three dimensional) neural tissue composition, the method comprising the steps of re-suspending cells that are obtained by culturing pluripotent stem cells in a neural induction medium in cell culture substrate and culturing said resuspended cells in the presence of an neural differentiation medium.

Abstract: A culture medium and a culture method for neural cells, particularly relating to a composition comprises a SMAD signaling pathway inhibitor, a SHH signaling pathway agonist, a Wnt signaling pathway agonist and a Myosin II ATPase inhibitor, optionally, it further comprises a ROCK inhibitor; or, the composition consists of the SMAD signaling pathway inhibitor, the SHH signaling pathway agonist, the Wnt signaling pathway agonist, the Myosin II ATPase inhibitor, and optionally the ROCK inhibitor. The same batch of neural cells, such as midbrain dopaminergic progenitors, can be efficiently obtained by using the culture method and culture medium designed on the basis of the composition.

Abstract: The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into cortical neurons, and cortical neurons generated by such methods. The presently disclosed subject matter also provides for uses of such cortical neurons for treating neurodegenerative CNS disorders.

Abstract: There is provided a production method for microglia, including a step of introducing, into pluripotent stem cells, a nucleic acid including an open reading frame of a transcription factor that increases expression of a Complement C3 (C3) gene. In the production method, the transcription factor is selected from the group consisting of SPI1, CEBPA, PTAFR, FLI1, MEF2C, EGR2, RUNX1, TNF, CEBPB, IKZF1, KLF6, NFIC, ELF4, PAX8, PRDM1, MEF2A, and NR4A3.

Abstract: Provided herein are compositions comprising CD4+ stem cell like memory T (TSCM) cells and their uses in the treatment of cancer, infection and autoimmune disorders.

Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.

Abstract: Natural Treg (nTreg) can potentially suppress cell immune response. Consequently, these CD4+ CD25+ CD127low Foxp3+ T cells are used in adoptive therapy against autoimmune and GVH disease. One difficulty is the varying functional properties depending on the microenvironment that may cause the loss of their suppressive activity and promote TH17- induced inflammatory effects. By ex vivo transdetermination of CD31 TH0 cells, the inventors established and expanded a Foxp3 regulatory T cell population (CD31d-Treg cells) functionally committed to exert a permanent Ag-specific regulatory activity whichever the microenvironmental conditions are. By contrast to nTreg cells, CD31d-Treg cells do not express the IL1 Receptor whose activation is required for IL-17 production. Accordingly, the present invention relates to a population of CD31d-Treg cells functionally committed to exert a regulatory activity and their use for Treg-based adoptive therapy.

Abstract: The present invention relates to a method for in vitro production of red blood cells. The method for in vitro production of red blood cells, according to the present invention, specifies, by cell size, the maturation step of cells exhibiting optimal effects in an agitation-type culture, so that even if an expert does not always identify cell shape, automated processes of culturing are possible, and thus automation in bioreactors is possible in the mass-production of uniform quality and red blood cells.

Abstract: This disclosure provides methods for producing neutrophils under serum-free and feeder-free conditions from protein tyrosine phosphatase 1B (PTP1b)-inhibited pluripotent stem cells. The disclosure further provides PTP1b inhibited neutrophils and uses thereof. Also disclosed are methods for producing human neutrophil-DC hybrid cells and human neutrophil-DC hybrid cells produced thereby.

Abstract: Aspects of the present disclosure relate to methods and compositions related to the preparation of immune cells, including engineered invariant natural killer T (iNKT) cells for off-the-shelf use for COVID-19 clinical therapy. The iNKT cells may be produced from hematopoietic stem progenitor cells and are suitable for allogeneic cellular therapy.

Abstract: The invention relates to an isolated cell having, after culturing a pluripotent stem cell (PSC) in a medium comprising a WNT agonist and an ACTIVIN antagonist, increased HOXA gene expression relative to a PSC not cultured in a medium comprising a WNT agonist and an ACTIVIN antagonist, wherein the cell with increased HOXA gene expression is capable of generating a definitive haematopoietic stem/precursor cell. The invention also relates to use of the cell for generating a definitive haematopoietic stem/precursor cell, and a method for differentiating a PSC into a definitive haematopoietic stem/precursor cell and a definitive haematopoietic stem/progenitor cell differentiated from a PSC by the method. The invention further relates to a therapeutic composition comprising a cell of the invention, and to therapeutic methods and uses of a cell of the invention.

Abstract: Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.

Abstract: A bioink comprises a cell solution comprising living cells and a cell culture medium, and a self-assembling peptide solution comprising a self-assembling peptide. The bioink is formed by mixing and extruding the cell solution and the self-assembling peptide solution together, and the bioink can be continuously extruded from the mixer after mixing. Useful methods of making bioinks and are also disclosed.

Abstract: A jammed gel bioink comprises a self-assembling peptide solution comprising a self-assembling peptide, and a cell solution comprising living cells and a cell culture medium. The self-assembling peptide solution is extruded to form an object, and then the cell solution is injected into the object. Useful methods of making the jammed gel bioink are also disclosed.

Abstract: Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.

Abstract: The present invention relates to methods for preparing in vitro models of nonalcoholic steatohepatitis.

Abstract: Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor and/or survival factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes a survival factor, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor and/or a different survival factor.

Abstract: The present invention relates to a method for producing a three-dimensional tissue body, including: a step of obtaining a mixture by mixing a cationic substance and a fragmented extracellular matrix component with cells; and a step of culturing the cells after the step of obtaining the mixture.

Abstract: The present disclosure provides infectious recombinant adeno-associated virus (rAAV) virions that comprise a variant capsid protein and a heterologous nucleic acid. The present disclosure further provides the variant adeno-associated virus (AAV) capsid proteins (and/or a nucleic acid encoding the variant AAV capsid proteins), which confer to an infectious rAAV virion an increased resistance to human AAV neutralizing antibodies. The present disclosure further provides host cells comprising an infectious rAAV virion and/or a nucleic acid encoding a subject variant AAV capsid protein. The present disclosure further provides methods of delivering a heterologous nucleic acid to a target cell where the target cell is contacted with a subject infectious rAAV virion. The present disclosure further provides methods of delivering a gene product to an individual, the methods generally involving administering an effective amount of a subject rAAV virion to an individual in need thereof.

Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.

Abstract: Provided is a carbon monoxide (CO) dehydrogenase with increased oxygen resistance and/or enzyme activity, specifically, a mutant CO dehydrogenase with increased oxygen resistance and/or enzyme activity by mutating amino acid residues. The CO dehydrogenase may detoxify toxic carbon monoxide at room temperature and pressure by easily oxidizing carbon monoxide and converting the same into carbon dioxide, and may effectively oxidize carbon monoxide even in gas including oxygen. Furthermore, since it is possible to remove carbon monoxide, which is emitted in large quantities in industries such as petrochemical and steel industries, cigarette burning, household cooking, various boilers, and combustion, through cigarette filters, air purifiers, intake filters in household cooking equipment, gas boilers, etc. the CO dehydrogenase may be utilized in various ways.

Abstract: The present invention relates to the production of chemical species in bacterial host cells. Particularly, the present invention provides for the production of chemical species in Escherichia coli (E. coli) host cells that functionally express engineered P450 enzymes.

Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein an alpha-amylase and a thermostable hemicellulase is present and/or added during liquefaction. The invention also relates to compositions suitable for use in processes of the invention.

Abstract: The present invention provides a novel hydrolase that can industrially produce optically highly pure (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid with high efficiency at low costs, and a production method using the hydrolase.

Abstract: Provided are compositions and methods that include one or more of: (1) a “CasZ” protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a “CasZ trancRNA”), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.